FDA Halts Cancer Trial After Deaths

The US Food and Drug Administration has ordered Juno Therapeutics to suspend its Phase II immunotherapy trials with adult patients suffering from relapsed or refractory B cell acute lymphoblastic leukemia after the biopharmaceutical company confirmed that three of its participants have died.

Juno’s CEO, Hans Bishop, said the three patients died as the result of cerebral edema, brain swelling caused by the presence of excessive fluid. One of the deaths occurred in May, the other two on a more recent, unspecified, date.

The company said investigators believe the cause most likely to have been to be the addition of fludarabine to the pre-conditioning regimen, a one-time primer for treatment. In this particular course of treatment, pre-conditioning consisted of a heavy dose of chemotherapy to kill off existing cancer cells and thus give the new, cancer-killing T-cells room to grow.

In a conference call with US media, Bishop said fludarabine had been shown to increase efficacy in previous studies, which is why it was added to the pre-conditioning regimen in this trial. However, he said, an “unforeseen interaction” between fludarabine and the JCAR015 cells proved to be lethal.

Juno said it was submitting revised protocols, consent forms and brochures to the FDA, as requested, and petitioning the agency to continue the trial with modifications, in particular dropping fludarabine from pre-conditioning in favor of a cyclophosphamide-only regimen.

Safety in clinical is coming increasingly under scrutiny in the wake of recent fatalities. In France, the health ministry has presented a plan to tighten rules governing human drug trials an incident in Rennes in January led to the death of one volunteer and left five others in serious or critical condition.

The French incident, called the worst of its kind ever in the country, led to the suspension of tests with the medication manufactured by Portugal’s Bial and designed to treat Alzheimer’s and Parkinson’s diseases.

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read

Photo
27.03.2025 • News

J&J to Invest $55 Billion in US Operations

US healthcare giant Johnson & Johnson (J&J) has unveiled plans to invest over $55 billion in the US over the next four years. This significant investment marks a 25% increase compared to the previous four years, the company said.

Photo
24.01.2025 • News

And the Winners are: Cynio, EnaDyne and Green Li-ion

The CHEManager Innovation Pitch, the start-up promotion initiative of CHEManager and CHEManager International, has given more than 100 start-ups from over 15 countries the opportunity to present their innovative ideas, products and technologies to a broad target group since its launch in 2019.

Photo
29.10.2024 • News

GSK to Invest $800 Million in US Manufacturing Facility

British pharma company GlaxoSmithKline (GSK) plans to invest up to $800 million to expand drug substance and drug product manufacturing capabilities at the company’s US site in Marietta, Pennsylvania. The investment, which GSK said is its largest ever in US manufacturing, is expected to create more than 200 new jobs.

Photo
19.03.2025 • NewsInnovation

Data-Driven Enzyme Immobilization

Inseit, based in Bern, develops biocatalysts for industrial setups using enzyme immobilization and biocomputation. Addressing biotech and sustainability challenges, Inseit was selected for Venture Leaders Biotech and won two Nucleate accelerator prizes.